ABSCI CORP Research and Development Expense
ABSCI CORP (ABSI) reported Research and Development Expense of $22.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- ABSCI CORP research and development expense for the quarter ending 2026-06-30 was $22.62M, a 10.55% increase year-over-year.
- ABSCI CORP research and development expense for the quarter ending 2026-03-31 was $19.27M, a 17.79% increase year-over-year.
- ABSCI CORP research and development expense for the quarter ending 2025-12-31 was $25.35M, a 37.93% increase year-over-year.
- ABSCI CORP research and development expense for the quarter ending 2025-09-30 was $19.25M, a 7.03% increase year-over-year.
- ABSCI CORP research and development expense for fiscal 2025 was $81.42M, a 27.50% increase from fiscal 2024.
- ABSCI CORP research and development expense for fiscal 2024 was $63.86M, a 32.85% increase from fiscal 2023.
- ABSCI CORP research and development expense for fiscal 2023 was $48.07M, a 18.40% decline from fiscal 2022.
- ABSCI CORP research and development expense for fiscal 2022 was $58.91M, a 32.12% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.62M 10-Q · filed 2026-08-11 | $41.89M 10-Q · filed 2026-08-11 | $67.24M derived: sum of 3 quarters · filed 2026-08-11 | $86.49M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $19.27M 10-Q · filed 2026-05-07 | $44.62M derived: sum of 2 quarters · filed 2026-05-07 | $63.87M derived: sum of 3 quarters · filed 2026-05-07 | $84.33M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $25.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $44.60M derived: sum of 2 quarters · filed 2026-03-24 | $65.05M derived: sum of 3 quarters · filed 2026-08-11 | $81.42M 10-K · filed 2026-03-24 |
| 2025-09-30 | $19.25M 10-Q · filed 2025-11-12 | $39.71M derived: sum of 2 quarters · filed 2026-08-11 | $56.07M 10-Q · filed 2025-11-12 | $74.45M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $20.46M 10-Q · filed 2026-08-11 | $36.82M 10-Q · filed 2026-08-11 | $55.20M derived: sum of 3 quarters · filed 2026-08-11 | $73.18M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $16.36M 10-Q · filed 2026-05-07 | $34.74M derived: sum of 2 quarters · filed 2026-05-07 | $52.73M derived: sum of 3 quarters · filed 2026-05-07 | $67.99M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $18.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $36.36M derived: sum of 2 quarters · filed 2026-03-24 | $51.62M derived: sum of 3 quarters · filed 2026-03-24 | $63.86M 10-K · filed 2026-03-24 |
| 2024-09-30 | $17.98M 10-Q · filed 2025-11-12 | $33.25M derived: sum of 2 quarters · filed 2025-11-12 | $45.48M 10-Q · filed 2025-11-12 | $57.75M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $15.26M 10-Q · filed 2025-08-12 | $27.50M 10-Q · filed 2025-08-12 | $39.77M derived: sum of 3 quarters · filed 2025-08-12 | $50.80M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $12.24M 10-Q · filed 2025-05-13 | $24.50M derived: sum of 2 quarters · filed 2025-05-13 | $35.53M derived: sum of 3 quarters · filed 2025-05-13 | $47.65M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $12.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $23.30M derived: sum of 2 quarters · filed 2025-03-18 | $35.41M derived: sum of 3 quarters · filed 2025-03-18 | $48.07M 10-K · filed 2025-03-18 |
| 2023-09-30 | $11.03M 10-Q · filed 2024-11-12 | $23.14M derived: sum of 2 quarters · filed 2024-11-12 | $35.80M 10-Q · filed 2024-11-12 | $47.11M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $12.11M 10-Q · filed 2024-08-14 | $24.77M 10-Q · filed 2024-08-14 | $36.08M derived: sum of 3 quarters · filed 2024-08-14 | $51.61M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $12.66M 10-Q · filed 2024-05-14 | $23.97M derived: sum of 2 quarters · filed 2024-05-14 | $39.50M derived: sum of 3 quarters · filed 2024-05-14 | $55.74M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $11.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $26.84M derived: sum of 2 quarters · filed 2024-03-21 | $43.08M derived: sum of 3 quarters · filed 2024-03-21 | $58.91M 10-K · filed 2024-03-21 |
| 2022-09-30 | $15.53M 10-Q · filed 2023-11-14 | $31.77M derived: sum of 2 quarters · filed 2023-11-14 | $47.59M 10-Q · filed 2023-11-14 | $63.36M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $16.24M 10-Q · filed 2023-08-14 | $32.07M 10-Q · filed 2023-08-14 | $47.83M derived: sum of 3 quarters · filed 2023-08-14 | $58.56M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $15.83M 10-Q · filed 2023-05-15 | $31.59M derived: sum of 2 quarters · filed 2023-05-15 | $42.32M derived: sum of 3 quarters · filed 2023-05-15 | $53.36M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $15.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $26.50M derived: sum of 2 quarters · filed 2023-03-30 | $37.54M derived: sum of 3 quarters · filed 2023-03-30 | $44.59M 10-K · filed 2023-03-30 |
| 2021-09-30 | $10.73M 10-Q · filed 2022-11-09 | $21.77M derived: sum of 2 quarters · filed 2022-11-09 | $28.82M 10-Q · filed 2022-11-09 | $33.42M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $11.04M 10-Q · filed 2022-08-11 | $18.09M 10-Q · filed 2022-08-11 | $22.69M derived: sum of 3 quarters · filed 2022-08-11 | $25.38M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $7.05M 10-Q · filed 2022-05-11 | $11.65M derived: sum of 2 quarters · filed 2022-05-11 | $14.34M derived: sum of 3 quarters · filed 2022-05-11 | $16.59M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $7.29M derived: sum of 2 quarters · filed 2022-03-22 | $9.54M derived: sum of 3 quarters · filed 2022-03-22 | $11.45M 10-K · filed 2022-03-22 |
| 2020-09-30 | $2.69M 10-Q · filed 2021-11-09 | $4.94M derived: sum of 2 quarters · filed 2021-11-09 | $6.85M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $2.25M 10-Q · filed 2021-09-07 | $4.16M 10-Q · filed 2021-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |